• +1-646-491-9876
    • +91-20-67278686

    Search

    Reflux Esophagitis-Pipeline Review H2 2017

    Reflux Esophagitis-Pipeline Review H2 2017

    • Report Code ID: RW0001881444
    • Category Life Sciences
    • No. of Pages 77
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline Review H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline Review H2 2017 provides an overview of the Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline landscape.

    When the liquid content of the stomach refluxes into the oesophagus that condition is called Gastroesophageal reflux disease (GERD) . It is a chronic condition. The symptoms of GERD are nausea heartburn and vomiting. The predisposing factors include eating large meals which can cause the Lower Esophageal Sphincter (LES) to open inappropriately as well as obesity pregnancy greasy food and certain drugs.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) complete with analysis by stage of development drug target mechanism of action (MoA) route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases.

    The Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes the molecules developed by Companies in Phase III Phase II Phase I and Preclinical stages are 4 5 5 and 6 respectively. Similarly the Universities portfolio in Preclinical stages comprises 1 molecules respectively.

    Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) .
    - The pipeline guide reviews pipeline therapeutics for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details R&D brief MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) therapeutics based on mechanism of action (MoA) drug target route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal)

    Reasons to buy

    - Procure strategically important competitor information analysis and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Reflux Esophagitis (Gastroesophageal Reflux Disease)-Overview
    Reflux Esophagitis (Gastroesophageal Reflux Disease)-Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Reflux Esophagitis (Gastroesophageal Reflux Disease)-Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Reflux Esophagitis (Gastroesophageal Reflux Disease)-Companies Involved in Therapeutics Development
    Ahn-Gook Pharmaceutical Co Ltd
    Cempra Inc
    Daewoong Pharmaceutical Co Ltd
    Eisai Co Ltd
    Ilyang Pharmaceutical Co Ltd
    Ironwood Pharmaceuticals Inc
    Jeil Pharmaceutical Co Ltd
    RaQualia Pharma Inc
    Takeda Pharmaceutical Company Ltd
    Wockhardt Ltd
    Yooyoung Pharm Co Ltd
    Yuyu Pharma Inc
    Reflux Esophagitis (Gastroesophageal Reflux Disease)-Drug Profiles
    (lansoprazole + omeprazole)-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ceclazepide-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CEM-031-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dexlansoprazole DR-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DWJ-1367-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DWP-14012-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    E-3710-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    G-17DT-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ilaprazole DR-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IW-3718-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    JP-1366-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    naronapride-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    netazepide-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pantoprazole-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RQ-00000774-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit Potassium Transporting ATPase Alpha Chain 1 Inhibitor for Peptic Ulcers and Reflux Esophagitis-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Tubulin for Barrett's Esophageal Adenocarcinoma-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tegoprazan-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tenatoprazole-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    YY-DXR-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    YYD-601-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Reflux Esophagitis (Gastroesophageal Reflux Disease)-Dormant Projects
    Reflux Esophagitis (Gastroesophageal Reflux Disease)-Discontinued Products
    Reflux Esophagitis (Gastroesophageal Reflux Disease)-Product Development Milestones
    Featured News & Press Releases
    Mar 09 2017 Ironwood Pharmaceuticals provides update on key pipeline program IW-3718 at R&D Day 2017
    Nov 16 2016 Renexxion Achieves Positive FDA Guidance for Phase 3-ready GI Drug Naronapride
    Jul 11 2016 Takeda Announces FDA Approval of Dexilant (dexlansoprazole) for Patients 12-17 Years of Age
    Mar 23 2016 Ironwood Pharmaceuticals Initiates Phase IIb Clinical Trial of IW-3718 in Refractory Gastroesophageal Reflux Disease
    Feb 18 2016 RaQualia Receives a Patent Allowance for Acid Pump Antagonist in Korea
    Jan 27 2016 FDA Approves Takeda's Dexilant SoluTab (dexlansoprazole)
    Oct 19 2015 Ironwood Highlights Refractory GERD Research at the American College of Gastroenterology 2015 Annual Scientific Meeting
    Feb 04 2015 Ironwood Reports Positive Top-Line Data from Exploratory Phase IIa Trial Of IW-3718 in Refractory Gastroesophageal Reflux Disease
    Mar 18 2014 Ironwood Pharmaceuticals Initiates Phase II Clinical Study of IW-3718 in Refractory Gastroesophageal Reflux Disease
    Dec 19 2013 Dexlansoprazole a New Dual-Delayed Release Technology for the Treatment Of Reflux Disease Accepted for National Approvals Within the European Union
    Dec 19 2013 Dexlansoprazole a New Dual-Delayed Release Technology for the Treatment Of Reflux Disease Accepted for National Approvals Within the European Union
    Oct 15 2013 TWi Pharmaceuticals Comments on Dexilant Ruling
    Sep 04 2012 Santarus Announces Appellate Court Reversal In Part Of Zegerid Invalidity Decision
    Nov 17 2011 Takeda Provides Update On DEXILANT Product Labeling
    Jul 27 2011 Ilyang Pharmaceuticals Obtains Patent For Ilaprazole
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease) H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products under Development by Universities/Institutes H2 2017
    Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017 (Contd..1) H2 2017
    Products under Development by Universities/Institutes H2 2017
    Number of Products by Stage and Target H2 2017
    Number of Products by Stage and Mechanism of Action H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline by Ahn-Gook Pharmaceutical Co Ltd H2 2017
    Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline by Cempra Inc H2 2017
    Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline by Daewoong Pharmaceutical Co Ltd H2 2017
    Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline by Eisai Co Ltd H2 2017
    Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline by Ilyang Pharmaceutical Co Ltd H2 2017
    Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline by Ironwood Pharmaceuticals Inc H2 2017
    Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline by Jeil Pharmaceutical Co Ltd H2 2017
    Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline by RaQualia Pharma Inc H2 2017
    Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline by Takeda Pharmaceutical Company Ltd H2 2017
    Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline by Wockhardt Ltd H2 2017
    Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline by Yooyoung Pharm Co Ltd H2 2017
    Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline by Yuyu Pharma Inc H2 2017
    Reflux Esophagitis (Gastroesophageal Reflux Disease)-Dormant Projects H2 2017
    Reflux Esophagitis (Gastroesophageal Reflux Disease)-Dormant Projects H2 2017 (Contd..1) H2 2017
    Reflux Esophagitis (Gastroesophageal Reflux Disease)-Dormant Projects H2 2017 (Contd..2) H2 2017
    Reflux Esophagitis (Gastroesophageal Reflux Disease)-Discontinued Products H2 2017
    Reflux Esophagitis (Gastroesophageal Reflux Disease)-Discontinued Products H2 2017 (Contd..1) H2 2017

    List of Figures

    Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease) H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products by Targets H2 2017
    Number of Products by Stage and Targets H2 2017
    Number of Products by Mechanism of Actions H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Routes of Administration H2 2017
    Number of Products by Stage and Routes of Administration H2 2017
    Number of Products by Molecule Types H2 2017
    Number of Products by Stage and Molecule Types H2 2017
    Ahn-Gook Pharmaceutical Co Ltd
    Cempra Inc
    Daewoong Pharmaceutical Co Ltd
    Eisai Co Ltd
    Ilyang Pharmaceutical Co Ltd
    Ironwood Pharmaceuticals Inc
    Jeil Pharmaceutical Co Ltd
    RaQualia Pharma Inc
    Takeda Pharmaceutical Company Ltd
    Wockhardt Ltd
    Yooyoung Pharm Co Ltd
    Yuyu Pharma Inc

    Request for Sample

    Report Url https://www.reportsweb.com//reflux-esophagitis-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//reflux-esophagitis-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//reflux-esophagitis-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments